nach oben

Die Pathologie

Erschienen in:

12.09.2022 | Referate: Preisträgerinnen und Preisträger – Novartis-Preis der DGP

IL-2/IL-2R signaling and IL-2Rα-targeted therapy in anaplastic large cell lymphoma

verfasst von: Huan-Chang Liang, PhD

Erschienen in: Die Pathologie | Sonderheft 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Anaplastic large cell lymphoma (ALCL) is a CD30-positive non-Hodgkin’s T‑cell lymphoma. Despite the implementation of CD30 antibody–drug conjugate-targeted therapy into front-line treatment regimens, the prognosis of some subtypes of the disease remains unsatisfactory. In the relapsed/refractory setting, effective second-line treatment options are still lacking. However, it has been reported that blockade of direct downstream targets of activator protein‑1 (AP-1) transcription factors, which are highly dysregulated in ALCL, results in complete and sustained remission in late-stage relapsed/refractory anaplastic lymphoma kinase (ALK)-positive ALCL patients. Moreover, it has been identified that involvement of the BATF3/AP‑1 module promotes lymphomagenesis via oncogenic BATF3/IL-2/IL-2R signaling through hyperphosphorylation of ERK1/2, STAT1, and STAT5 in ALCL cells regardless of their ALK status. Therefore, targeting BATF3/IL-2/IL-2R signaling may represent a novel therapeutic alternative for ALCL patients.

Vose J, Armitage J, Weisenburger D et al (2008) International peripheral T‑cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130CrossRef

Greer J, Kinney M, Collins R et al (1991) Clinical features of 31 patients with Ki‑1 anaplastic large-cell lymphoma. J Clin Oncol 9:539–547CrossRef

Swerdlow S, Campo E, Harris N et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. World Health Organization, Geneva

Garces de los Fayos Alonso I, Liang HC, Turner SD et al (2018) The role of activator protein‑1 (AP-1) family members in CD30-positive lymphomas. Cancers (Basel) 10:E93CrossRef

Crescenzo R, Abate F, Lasorsa E et al (2015) Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516–532CrossRef

Agnelli L, Mereu E, Pellegrino E et al (2012) Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood 120:1274–1281CrossRef

Schleussner N, Merkel O, Costanza M et al (2018) The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia 32:1994–2007CrossRef

Liang HC, Costanza M, Prutsch N et al (2021) Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma. Nat Commun 12:5577CrossRef

Chen J, Zhang Y, Petrus MN et al (2017) Cytokine receptor signaling is required for the survival of ALK-anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. Proc Natl Acad Sci USA 114:3975–3980CrossRef

10.

Lamant L, de Reyniès A, Duplantier M et al (2007) Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109:2156–2164CrossRef

11.

Iqbal J, Weisenburger DD, Greiner TC et al (2010) Molecular signatures to improve diagnosis in peripheral T‑cell lymphoma and prognostication in angioimmunoblastic T‑cell lymphoma. Blood 115:1026–1036CrossRef

12.

Boulland ML, Meignin V, Leroy-Viard K et al (1998) Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol 153:1229–1237CrossRef

13.

Bard DJ, Gelebart P, Anand M et al (2008) Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 22:1595–1603CrossRef

14.

Prutsch N, Gurnhofer E, Suske T et al (2019) Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia 33:696–709CrossRef

15.

Prokoph N, Probst N, Lee L et al (2020) IL10RA modulates crizotinib sensitivity in NPM1-ALK-positive anaplastic large cell lymphoma. Blood 136:1657–1669

16.

Couronné L, Scourzic L, Pilati C et al (2013) STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 98:1748–1752CrossRef

17.

Ehrentraut S, Schneider B, Nagel S et al (2016) Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T‑cell lymphoma. Oncotarget 7:34201–34216CrossRef

18.

Silva DA, Yu S, Ulge UY et al (2019) De novo design of potent and selective mimics of IL‑2 and IL-15. Nature 565:186–191CrossRef

19.

Waldmann TA (2015) The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res 3:219–227CrossRef

20.

Zhang Q, Wang HY, Liu X et al (2011) IL-2R common γ‑chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci USA 108:11977–11982CrossRef

21.

Pomari E, Basso G, Bresolin S et al (2017) NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma. Leukemia 31:498–501CrossRef

22.

Dinarello CA (2007) Historical review of cytokines. Eur J Immunol 37:S34–S45CrossRef

23.

Liao W, Lin J‑X, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38:13–25CrossRef

24.

Müller MR, Rao A (2010) NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 10:645–656CrossRef

25.

Lechner MG, Megiel C, Church CH et al (2012) Survival signals and targets for therapy in breast implant-associated ALK-anaplastic large cell lymphoma. Clin Cancer Res 18:4549–4559CrossRef

26.

Ito M, Zhao N, Zeng Z et al (2011) Interleukin‑2 functions in anaplastic large cell lymphoma cells through augmentation of extracellular signal-regulated kinases 1/2 activation. Int J Biomed Sci 7:181–190

27.

Knörr F, Damm-Welk C, Ruf S et al (2018) Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica 103:477–485CrossRef

28.

Lodolce JP, Burkett PR, Koka RM et al (2002) Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 13:429–439CrossRef

29.

Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97:14–32CrossRef

30.

Ullrich K, Blumenthal-Barby F, Lamprecht B et al (2015) The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells. Leukemia 29:1213–1218CrossRef

31.

Brugières L, Le Deley MC, Rosolen A et al (2009) Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL group. J Clin Oncol 27:897–903CrossRef

32.

Wrobel G, Mauguen A, Rosolen A et al (2011) Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer 56:1071–1077CrossRef

33.

Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821CrossRef

34.

Pro B, Advani R, Brice P et al (2014) Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 124:3095CrossRef

35.

Richardson N, Kasamon Y, Chen H et al (2019) FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T‑cell lymphoma. Oncologist 24:180–187CrossRef

36.

Horwitz S, O’Connor OA, Pro B et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T‑cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393:229–240CrossRef

37.

Attia P, Maker AV, Haworth LR et al (2005) Inability of a fusion protein of IL‑2 and diphtheria toxin (denileukin diftitox, DAB389IL‑2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 28:582–592CrossRef

38.

Lansigan F, Stearns DM, Foss F (2010) Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T‑cell lymphoma. Cancer Manag Res 2:53–59CrossRef

39.

LeMaistre CF, Saleh MN, Kuzel TM et al (1998) Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin‑2. Blood 91:399–405

40.

Duvic M, Cather J, Maize J, Frankel AE (1998) DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T‑cell lymphoma. Am J Hematol 58:87–90CrossRef

41.

Prince HM, Duvic M, Martin A et al (2010) Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T‑cell lymphoma. J Clin Oncol 28:1870–1877CrossRef

42.

Wang Z, Zheng Q, Zhang H et al (2017) Ontak-like human IL‑2 fusion toxin. J Immunol Methods 448:51–58CrossRef

43.

Flynn MJ, Zammarchi F, Tyrer PC et al (2016) ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther 15:2709–2721CrossRef

Titel: IL-2/IL-2R signaling and IL-2Rα-targeted therapy in anaplastic large cell lymphoma
verfasst von: Huan-Chang Liang, PhD
Publikationsdatum: 12.09.2022
Verlag: Springer Medizin
Erschienen in: Die Pathologie / Ausgabe Sonderheft 1/2022
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-022-01108-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

IL-2/IL-2R signaling and IL-2Rα-targeted therapy in anaplastic large cell lymphoma

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2022

Bericht über die Sitzung der AG Hämatopathologie anlässlich der 105. Tagung der Deutschen Gesellschaft für Pathologie in Münster 2022

Update Thoraxpathologie 2022 – Bericht der Arbeitsgemeinschaft Thoraxpathologie der Deutschen Gesellschaft für Pathologie

Bericht der AG Kinder- und Fetalpathologie

Rede des DGP-Vorsitzenden

Auf dem Weg zum virtuellen Mikroskop: Synchrotron-basierte dreidimensionale Bildgebung in der Pathologie

Lasermikrodissektion zur Analyse molekularer Heterogenität im kolorektalen Karzinom

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin